Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas.
Eleven patients treated with intracarotid BCNU, cisplatinum, or BCNU and cisplatinum in combination for recurrent malignant gliomas were followed with serial ophthalmologic examinations for 2 to 11 months. Eight patients developed significant visual loss ipsilateral to the side of infusion. Secondary glaucoma and internal ophthalmoplegia were new complications observed after BCNU treatment. An unusual pigmentary retinopathy, previously unreported, was seen in patients treated with cisplatinum. One patient also developed a cavernous sinus syndrome after the intracarotid administration of cisplatinum.
Miller
D F
DF
Bay
J W
JW
Lederman
R J
RJ
Purvis
J D
JD
Rogers
L R
LR
Tomsak
R L
RL
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001932:Brain Neoplasms / Q000188:drug therapy*; D002330:Carmustine / Q000009:adverse effects*; D002339:Carotid Arteries; D002945:Cisplatin / Q000009:adverse effects*; D003231:Conjunctivitis / Q000139:chemically induced; D005128:Eye Diseases / Q000139:chemically induced*; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D007261:Infusions, Intra-Arterial; D007429:Intraocular Pressure / Q000187:drug effects; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D012025:Reflex, Pupillary / Q000187:drug effects; D012164:Retinal Diseases / Q000139:chemically induced; D014792:Visual Acuity / Q000187:drug effects
D002945:Cisplatin; D002330:Carmustine